Oyebimpe O. Adesina

Oyebimpe O. Adesina

Auto-generated profile, based on publicly available information

Oyebimpe O. Adesina

Center for Oncology Hematology Outcomes Research and Training, Division of Hematology and Oncology University of California Davis Comprehensive Cancer Center Sacramento California USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
OAOyebimpe Adesina
Oyebimpe Adesina
ABAnn Brunson
Ann Brunson
TKTheresa H. M. Keegan
Theresa H. M. Keegan
TWTed Wun
Ted Wun
Key Points: In sickle cell disease, ONFH incidence accelerates in early adulthood. Frequent hospitalizations and antecedent acute chest syndrome are independently associated with sickle cell–related ONFH.

6 December 2019 in Hematology-American Society Hematology Education Program
Verified
Journal Article
Open access
PDF file
OAOyebimpe O. Adesina
Oyebimpe O. Adesina
LNLynne D. Neumayr
Lynne D. Neumayr
Osteonecrosis, a form of ischemic bone injury that leads to degenerative joint disease, affects ∼30% of people with sickle cell disease. Although osteonecrosis most commonly affects the femoral head (often bilaterally, with asymmetric clinical and radiographic progression), many people with sickle cell disease also present with multifocal joint involvement. We present the case of a young woman with bilateral osteonecrosis of the femoral head at varying stages of progression; we also highlight other important comorbid complications (eg, chronic pain requiring long-term opioids, debility, and social isolation) and postoperative outcomes. In this review, partly based on recommendations on osteonecrosis management from the 2014 evidence-based report on sickle cell disease from the National Heart, Lung and Blood Institutes, we also discuss early signs or symptoms of osteonecrosis of the femoral head, radiographic diagnosis and staging criteria, hydroxyurea effect on progression to femoral head collapse, and surgical outcomes of total hip arthroplasty in the modern era. In summary, we failed to find an association between hydroxyurea use and femoral head osteonecrosis; we also showed that evidence-based perioperative sickle cell disease management resulted in superior postoperative outcomes after cementless total hip arthroplasty in sickle cell–related osteonecrosis of the femoral head.

4 January 2023 in American Journal of Hematology
Verified
Journal Article
Open access
OAOyebimpe O. Adesina
Oyebimpe O. Adesina
ABAnn Brunson
Ann Brunson
SFSamantha C. Fisch
Samantha C. Fisch
BYBo Yu
Bo Yu
AMAnjlee Mahajan
Anjlee Mahajan
TWTed Wun
Ted Wun
Adverse pregnancy outcomes occur frequently in women with sickle cell disease (SCD) across the globe. In the United States, Black women experience disproportionately worse maternal health outcomes than all other racial groups. To better understand how social determinants of health impact SCD maternal morbidity, we used California's Department of Health Care Access and Information data (1991–2019) to estimate the cumulative incidence of pregnancy outcomes in Black women with and without SCD—adjusted for age, insurance status, and Distressed Community Index (DCI) scores. Black pregnant women with SCD were more likely to deliver at a younger age, use government insurance, and live in at‐risk or distressed neighborhoods, compared to those without SCD. They also experienced higher stillbirths (26.8, 95% confidence interval [CI]: 17.5–36.1 vs. 12.4 [CI: 12.1–12.7], per 1000 births) and inpatient maternal mortality (344.5 [CI: 337.6–682.2] vs. 6.1 [CI: 2.3–8.4], per 100 000 live births). Multivariate logistic regression models showed Black pregnant women with SCD had significantly higher odds ratios (OR) for sepsis (OR 14.89, CI: 10.81, 20.52), venous thromboembolism (OR 13.60, CI: 9.16, 20.20), and postpartum hemorrhage (OR 2.25, CI 1.79–2.82), with peak onset in the second trimester, third trimester, and six weeks postpartum, respectively. Despite adjusting for sociodemographic factors, Black women with SCD still experienced significantly worse pregnancy outcomes than those without SCD. We need additional studies to determine if early introduction to reproductive health education, continuation of SCD‐modifying therapies during pregnancy, and increasing access to multidisciplinary perinatal care can reduce morbidity in pregnant women with SCD.

12 December 2024 in Blood
Verified
Journal Article
Closed access
OOOlubusola Oluwole
Olubusola Oluwole
ABAnn M. Brunson
Ann M. Brunson
OAOyebimpe O. Adesina
Oyebimpe O. Adesina
SWShaina M. Willen
Shaina M. Willen
TKTheresa H. M. Keegan
Theresa H. M. Keegan
TWTed Wun
Ted Wun
Neurovascular complications, including strokes and transient ischemic attacks (TIAs), are common and cause significant morbidity in individuals with sickle cell disease (SCD). The Stroke Prevention Trial in Sickle Cell Anemia (STOP) (1998) established chronic transfusions as the standard of care for children with SCD at high risk for stroke. Using statewide data from the California Department of Health Care Access and Innovation (1991-2019), we determined the cumulative incidence (CMI) and rates of primary and recurrent strokes/TIAs in people with SCD pre- and post-STOP trial. For the 7636 patients included in our SCD cohort, the cumulative incidence of the first ischemic stroke was 2.1% by the age of 20 years and 13.5% by the age of 60 years. The CMI of the first intracranial hemorrhage (ICH) was 0.5% and 6.8% by the age of 20 and 60 years, respectively. Ischemic stroke rates increased in children (age <18 years; 234.9 vs 165.1 per 100 000 patient years [PY]; P = .012) and adults (age 31-50 years; 431.1 vs 303.2 per 100 000 PY; P = .031) in 2010 to 2019 when compared with the preceding decade. There was an increase in the rates of ICH in those aged 18 to 30 years and TIA in children <18 years from 2010 to 2019 when compared with the previous decade. Risk factors for strokes included increasing age, hypertension, and hyperlipidemia. These findings underscore the need for stroke prevention in adults with SCD, suggesting an emphasis on management of modifiable cerebrovascular risk factors that have been proven to be effective in the general population.

9 May 2019 in Blood Advances
Verified
Journal Article
Closed access
PDF file
OAOyebimpe O. Adesina
Oyebimpe O. Adesina
JGJames G. Gurney
James G. Gurney
GKGuolian Kang
Guolian Kang
MVMartha Villavicencio
Martha Villavicencio
JHJason R Hodges
Jason R Hodges
JHJane S Hankins
Jane S Hankins
Low bone mineral density (BMD) disproportionately affects people with sickle cell disease (SCD). Growth faltering is common in SCD, but most BMD studies in pediatric SCD cohorts fail to adjust for short stature. We examined low BMD prevalence in 6- to 18-year-olds enrolled in the Sickle Cell Clinical Research and Intervention Program (SCCRIP), an ongoing multicenter life span SCD cohort study initiated in 2014. We calculated areal BMD for chronological age and height-adjusted areal BMD (Ht-aBMD) z scores for the SCCRIP cohort, using reference data from healthy African American children and adolescents enrolled in the Bone Mineral Density in Childhood Study. We defined low BMD as Ht-aBMD z scores less than or equal to –2 and evaluated its associations with demographic and clinical characteristics by using logistic regression analyses. Of the 306 children and adolescents in our study cohort (mean age, 12.5 years; 50% female; 64% HbSS/Sβ0-thalassemia genotype; 99% African American), 31% had low areal BMD for chronological age z scores and 18% had low Ht-aBMD z scores. In multivariate analyses, low Ht-aBMD z scores associated with adolescence (odds ratio [OR], 7.7; 95% confidence interval [CI], 1.94-30.20), hip osteonecrosis (OR, 4.0; 95% CI, 1.02-15.63), chronic pain (OR, 10.4; 95% CI, 1.51-71.24), and hemoglobin (OR, 0.74; 95% CI, 0.57-0.96). Despite adjusting for height, nearly 20% of this pediatric SCD cohort still had very low BMD. As the SCCRIP cohort matures, we plan to prospectively evaluate the longitudinal relationship between Ht-aBMD z scores and markers of SCD severity and morbidity. Key Points Despite adjusting for short stature, low BMD remains highly prevalent in adolescents with SCD. Low BMD independently associates with chronic pain and hip osteonecrosis in pediatric SCD. Visual Abstract

22 October 2024 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
OAOyebimpe O. Adesina
Oyebimpe O. Adesina
IJIsaac C. Jenkins
Isaac C. Jenkins
FGFábio Galvão
Fábio Galvão
AMAna C. de Moura
Ana C. de Moura
KFKleber Y. Fertrin
Kleber Y. Fertrin
SSSara T. Olalla Saad
Sara T. Olalla Saad
Summary Low bone mineral density is highly prevalent in sickle cell disease (SCD); whether bisphosphonates can safely preserve or increase bone mass in SCD adults remains unknown. In this study, lumbar spine bone density remained stable with alendronate use, and treatment-related side effects were mostly mild and self-limited. Purpose To describe the effects of alendronate in adults with sickle cell disease (SCD) and osteoporosis. Methods We reviewed retrospective clinical data from adults with SCD and osteoporosis treated with alendronate at a single center in Brazil (2009–2019). Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DXA) of the lumbar spine, femoral neck, and total hip. We analyzed BMD changes by alendronate treatment duration (months), stratified by sex, skeletal site, and SCD genotype. Results Sixty-four SCD adults with osteoporosis (69% females, 73% HbSS, mean age ± standard deviation 42.4 ± 10.9 years) received alendronate for a median (interquartile range) of 48 (29, 73) months. Compared with males, females had significantly lower baseline BMD (g/cm2) at the femoral neck (0.72 vs 0.85, p = < 0.001) and total hip (0.79 vs 0.88, p = 0.009). The between-sex differences in BMD changes were insignificant. Mean lumbar spine BMD significantly changed by 0.0357 g/cm2 (p = 0.028) in those on alendronate for > 5 years. Four adults (6.3%) reported mild therapy-related side effects. An atypical femoral diaphysis fracture, attributed to alendronate, was incidentally noted in a 37-year-old man on treatment for 4 years. Conclusion In this retrospective cohort of adults with SCD and osteoporosis on alendronate for a median of 48 months, we found no significant interactions between sex and changes in lumbar spine, femoral neck, or total hip BMD with alendronate. Lumbar spine BMD was stable in those on alendronate for < 5 years. Side effects of alendronate were mild, though one patient developed an atypical femoral fracture.